All In Biotech

Drug Trial Radar · NCT03475342

World Maternal Antifibrinolytic Trial_2

Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.

Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 15,068 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15,068

Actual

Start

Aug 24, 2019

Primary completion

Sep 20, 2023

Study completion Oct 29, 2023

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wellcome Trust; Bill and Melinda Gates Foundation
First posted
Mar 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. However, for many women, treatment of PPH is too late to prevent death and severe morbidities. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. We now want to do the WOMAN-2 trial to see if giving tranexamic acid can prevent PPH and other severe outcomes in women with moderate and severe anaemia.

Conditions

  • Intrapartum - Moderate and Severe Anaemia

Interventions

  • Tranexamic AcidDrug

    Ampoules and packaging for both arms will be identical in appearance.

  • PlaceboOther

    Ampoules and packaging for both arms will be identical in appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postpartum Haemorrhage (cause will be described)Time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • Mother & Child Hospital

    Akure, Nigeria

  • University of Medical Sciences Teaching Hospital

    Akure, Nigeria

  • Adeoyo Maternity Hospital

    Ibadan, Nigeria

  • Ilorin General Hospital

    Ilorin, Nigeria

  • Muhammad Abdullahi Wase Specialist Hospital

    Kano, Nigeria

  • Ladoke Akintola University of Technology Teaching Hospital

    Ogbomoso, Nigeria

  • State Hospital

    Oyo, Nigeria

  • Ayub Teaching Hospital (Unit A)

    Abbottabad, Pakistan

  • Ayub Teaching Hospital (Unit C)

    Abbottabad, Pakistan

  • Ayub Teaching Hospital Unit B

    Abbottabad, Pakistan

  • Bahawalpur Victoria Hospital

    Bahawalpur, Pakistan

  • Aziz Bhatti Teaching Hospital

    Gujrat, Pakistan

  • MCH PIMS

    Islamabad, Pakistan

  • Military Hospital

    Islamabad, Pakistan

  • Civil Hospital

    Karachi, Pakistan

  • Jinnah Postgraduate Medical Centre

    Karachi, Pakistan

  • Koohi Goth Hospital

    Karachi, Pakistan

  • Jinnah Hospital

    Lahore, Pakistan

  • Services Hospital

    Lahore, Pakistan

  • Sir Ganga Ram Hospital Unit 1

    Lahore, Pakistan

  • Sir Ganga Ram Hospital Unit 2

    Lahore, Pakistan

  • Sir Ganga Ram Hospital Unit 3

    Lahore, Pakistan

  • Sir Ganga Ram Hospital Unit 4

    Lahore, Pakistan

  • Chandka SMBBMU Sheikh Zaid Woman Hospital Unit 1

    Larkana, Pakistan

  • Chandka SMBBMU Sheikh Zaid Woman Hospital Units 2 & 3

    Lārkāna, Pakistan

  • Nishtar Hospital Unit 1

    Multan, Pakistan

  • Nishtar Hospital Unit 2

    Multan Khurd, Pakistan

  • Nishtar Hospital Unit 3

    Multan Khurd, Pakistan

  • Bolan Medical Centre

    Quetta, Pakistan

  • Benazir Bhutto Shaheed Hospital

    Rawalpindi, Pakistan

  • Federal Government Polyclinic

    Rawalpindi, Pakistan

  • Holy Family Hospital

    Rawalpindi, Pakistan

  • Mount Meru Regional Referral Hospital

    Arusha, Tanzania

  • Amana Regional Referral Hospital,

    Dar es Salaam, Tanzania

  • Muhimbili National Hospital

    Dar es Salaam, Tanzania

  • Temeke Regional Referral Hospital

    Dar es Salaam, Tanzania

  • Dodoma Regional Referral Hospital

    Dodoma, Tanzania

  • Tumbi Regional Referral Hospital, Kibaha

    Kibaha, Tanzania

  • Mwananyamala Regional Referral Hospital

    Kinondoni, Tanzania

  • Mbeya Zonal Referral Hospital

    Mbeya, Tanzania

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.